This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) beats earnings and sales estimates in the third quarter of 2019.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3
by Zacks Equity Research
Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.
AVEO Pharmaceuticals (AVEO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AVEO Oncology has been struggling lately, but the selling pressure may be coming to an end soon.
Reata (RETA) Jumps: Stock Rises 5. 6%
by Zacks Equity Research
Reata (RETA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
AVEO (AVEO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AVEO (AVEO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Renal Cell Carcinoma Space in Focus: Some Key Developments
by Ekta Bagri
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
AVEO (AVEO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AVEO Surges on Favorable Updated OS Results on RCC Drug
by Zacks Equity Research
AVEO posts positive updated results from the second prespecified overall survival analysis of Fotivda for treating highly refractory metastatic renal cell carcinoma. Stock up more than 30%.
Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.
AVEO (AVEO) Up 0.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss is narrower than expected in the second quarter of 2019. However, revenues fall short of estimates.
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of 66.67% and -60.39%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
AVEO Pharmaceuticals (AVEO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Pharmaceuticals Down More Than 50% YTD: Here's Why
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) suffers a major setback as it delays the NDA filing for Fotivda in the United States.
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO (AVEO) Down 19.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AVEO (AVEO) delivered earnings and revenue surprises of -20.00% and 117.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
AVEO Pharmaceuticals (AVEO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, AVEO Pharmaceuticals (AVEO) closed at $0.91, marking a -1.42% move from the previous day.